FutureTox V

New Technologies to Evaluate Organ-Specific Effects for Drugs and Chemicals

About FutureTox V

FutureTox V: New Technologies to Evaluate Organ-Specific Effects of Drugs and Chemicals will focus on issues of interest to regulatory and investigative toxicologists and discuss new technologies and strategies that are being used to improve, reduce, and/or replace animal testing (3Rs). The conference also will have presentations on computational analysis and artificial intelligence (AI). For example, new technologies will need to be developed to meet the computational challenges that genomics poses for the near future—given highly distributed data acquisition that involves heterogeneous formats—as well as emerging opportunities for data reduction and real-time analysis.

The FutureTox series focuses on building the road for 21st-century toxicology and risk assessment practices, utilizing in vitro data and in silico models for predictive toxicology, and taking the high-throughput risk assessment paradigm forward to address challenges in implementing the emerging big-data toolbox for risk assessment and regulatory decision-making.

Background and Vision for the Conference

  FutureTox V Will Address

  • Microphysiological Systems (MPS) and Engineered Microtissues:
    These represent 3D tissue function in a way that more realistically represents human organ function and can be used in efficacy and safety testing for pharma, disease models and therapies, and hazard identification for environmental chemical management programs. Important issues are in the capacity to recapitulate or invoke human disease processes utilizing integrated and translational multi-omics approaches, bioinformatics, AI-based computational models, and multi-chip circuits.

  • Novel Cross-Cutting Technologies:
    These involve single cell transcriptomics, novel imaging tools, and other emerging cutting-edge methods for breaking down cellular functions into subtype-specific effects that are topographically linked to tissue physiology and organ function. Elucidating “subtype cellular functions” promises to revolutionize the way to assess local changes in a tissue that cascade from toxicant-induced changes at single cell resolution to altered organ function.

  • Computational Integration and Synthesis:
    Mechanistic understanding of biological and toxicological processes is becoming increasingly dependent on big data. AI (e.g., machine and deep learning) and virtual-reality technologies are examples of data-related innovations that herald a new era for biomedical research, requiring quantitative systems for extracting knowledge and concepts.

  • Managing Expectations:
    Short-term and long-term activities for pragmatic use of technologies to answer questions on organ-specific toxicity (e.g., 2D versus 3D, screening versus targeted testing, in vitro to in vivo extrapolation, kinetics and dynamics, etc.) will be addressed in the discussion and breakout group sessions.

By presenting these cross-cutting topics (e.g., technology used in a tissue type and big data), it is expected that individuals working on the technology side will learn about potential new applications, scientists working on a type of toxicity will become educated about new approaches they might use in their field, and all will become acquainted with ways to store and utilize the resulting data.



The abstract submission period for FutureTox V will be announced at a later date.

Hotel Information

Hotel information will be announced at a later date.


Registration information for FutureTox V will be announced at a later date.

Organizing Committee

Chair: Ivan Rusyn, MD, PhD

Texas A&M University, College Station, TX

Co-Chair: Thomas B. Knudsen, PhD

US EPA/NCCT, Research Triangle Park, NC

Patrick Allard, PhD

University of California Los Angeles, CA

Jamie J. Bernard, PhD

Michigan State University, East Lansing, MI

Suzanne C. Fitzpatrick, PhD, DABT

SOT Council Contact
US FDA/CFSAN, College Park, MD

Jill A. Franzosa, PhD

US EPA, Research Triangle Park, NC

Kevin S. McDorman, DVM, PhD, DACVP

Charles River, Frederick, MD

Donna L. Mendrick, PhD

US FDA/NCTR, Silver Spring, MD

Xi Yang, PhD

Collaborative Conferences Committee Liaison
US FDA, Silver Spring, MD


Diamond Level

Society of Toxicology (SOT) Logo

Scientific Liasion Coalition (SLC) Logo

Become a Sponsor

Interested in becoming a sponsor? Learn about the opportunities and benefits of sponsorship.

Request Info


 11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191-4375